Evidence map›Paper›PMID 32532823›Full record

ArticleCancer research2020

Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.

Mireille Vankemmelbeke, Richard S McIntosh, Jia Xin Chua, Thomas Kirk, Ian Daniels, Marilena Patsalidou, Robert Moss, Tina Parsons, David Scott, Gemma Harris and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Mireille Vankemmelbeke *Academic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Richard S McIntosh *Academic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Jia Xin ChuaAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Thomas KirkAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.ORCID 0000-0002-5267-0431
Ian DanielsScancell Limited, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Marilena PatsalidouAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Robert MossAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
Tina ParsonsScancell Limited, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.
David ScottSchool of Biosciences, University of Nottingham, Sutton Bonington Campus, United Kingdom.ORCID 0000-0002-6726-2078
Gemma HarrisResearch Complex at Harwell, Rutherford Appleton Laboratory, Didcot, United Kingdom.ORCID 0000-0002-4587-4620
Judith M RamageAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.ORCID 0000-0003-1948-7974
Ian SpendloveAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom.ORCID 0000-0002-7480-3768
Lindy G DurrantAcademic Department of Clinical Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, United Kingdom. lindy.durrant@nottingham.ac.uk.
University of Nottingham · GBResearch Complex at Harwell · GB

Funding

Medical Research Council MR/M015564/1
6 · The paper itself

Abstract

Murine IgG3 glycan-targeting mAb often induces direct cell killing in the absence of immune effector cells or complement via a proinflammatory mechanism resembling oncotic necrosis. This cancer cell killing is due to noncovalent association between Fc regions of neighboring antibodies, resulting in enhanced avidity. Human isotypes do not contain the residues underlying this cooperative binding mode; consequently, the direct cell killing of mouse IgG3 mAb is lost upon chimerization or humanization. Using the Lewis

Indexed as

AnimalsAntibodies, MonoclonalAntibody AffinityAntibody-Dependent Cell CytotoxicityCell DeathCell Line, TumorColorectal NeoplasmsComplement System ProteinsFemaleGenetic EngineeringHumansImmunoglobulin Fc FragmentsImmunoglobulin GImmunotherapyMiceMice, Inbred BALB CAntibodies, MonoclonalComplement System ProteinsImmunoglobulin Fc FragmentsImmunoglobulin GPolysaccharides

Identifiers

PMID32532823
PMCPMC7611157
OpenAlexW3035682484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.